###begin article-title 0
###xml 142 150 <span type="species:ncbi:9606">Patients</span>
Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients
###end article-title 0
###begin p 1
###xml 188 196 <span type="species:ncbi:9606">patients</span>
Conceived and designed the experiments: ET MPP. Performed the experiments: ET. Analyzed the data: ET MPP. Contributed reagents/materials/analysis tools: RL. Wrote the paper: MPP. Provided patients' material and contributed helpful discussions: MB FG. Contributed helpful discussion: GP VD.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
Pancreatic cancer is a very aggressive disease with dismal prognosis; peculiar is the tumor microenvironment characterized by an extensive fibrotic stroma, which favors rapid tumor progression. We previously reported that pancreatic cancer patients have a selective Th2 skew in the anti-carcinoembryonic antigen (CEA) CD4+ T cell immunity, which correlates with the presence of a predominant GATA-3+ tumor lymphoid infiltrate. This has negative effects in both effective anti-tumor immunity and further favoring fibrinogenesis. Aim of this study was to evaluate whether the Th2 polarization of CEA-specific CD4+ T cells from pancreatic cancer patients is stable or can be reverted by immunomodulating cytokines.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 484 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 688 689 684 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 174 181 <span type="species:ncbi:9606">patient</span>
We first evaluated the influence of IL-12 and IL-27, as single agents and in association, on the polarization of CEA-specific Th2 CD4+ T cell clones from a pancreatic cancer patient. We found that only the combination of IL-12 and IL-27 modified the polarization of Th2 effectors by both reduction of IL-5, GM-CSF and IL-13 and induction of IFN-gamma production, which lasted after cytokine removal. Second, we evaluated the effect of the combined treatment on polyclonal CEA-specific CD4+ T cells in short-time re-stimulation assays. In agreement with the data obtained with the clones, we found that the combined treatment functionally modulated the Th2 polarization of CEA-specific CD4+ T cells and enhanced pre-existing Th1 type immunity.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Collectively, our results demonstrate that tumor antigen specific Th2 CD4+ T cells in pancreatic cancer are endowed with functional plasticity. Hence, loco-regional cytokines delivery or targeted therapy based on antibodies or molecules directed to the tumor stroma might improve anti-tumor immunity and ameliorate fibrosis, without systemic toxicity.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 74 77 74 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Warshaw1">[1]</xref>
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Kleeff1">[2]</xref>
Pancreatic cancer (PC) is a very aggressive disease with dismal prognosis [1]. Peculiar is the tumor microenvironment, which consists of fibroblasts, pancreatic stellate cells, endothelial cells, immune and endocrine cells and perineural spreading and it is believed to play an active role in disease progression and aggressiveness [2].
###end p 9
###begin p 10
###xml 9 12 9 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 551 552 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 679 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 737 738 729 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 887 888 879 880 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1007 1008 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1032 1033 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
Recently [3], we investigated the quality of the anti-tumor CD4+ T cell responses in PC patients undergoing surgical resection, by comparing the anti-carcinoembryonic (CEA) and anti-viral CD4+ T cell immunity. We found that anti-CEA CD4+ T cell immunity was present in a significantly lower number of PC patients compared to normal donors. Most importantly, while CD4+ T cells from normal donors produced mainly granulocytes macrophages colony stimulating factor (GM-CSF) and the pro-inflammatory (i.e., Th1) cytokine interferon-gamma (IFN-gamma), CD4+ T cells from the patients produced mainly interleukin(IL)-5 and IL-13, demonstrating a skew towards an anti-inflammatory (i.e., Th2) type. On the contrary, the extent of anti-viral CD4+ T cell immunity was comparable between the two groups and showed a Th1 type. In agreement with the Th2 skew observed in circulating CEA specific CD4+ T cells, immunohistochemical analysis of tumor infiltrating lymphocytes showed a significantly higher number of GATA-3+ (Th2) compared to T-bet+ (Th1) lymphoid cells, supporting a Th2 skew also at the tumor site.
###end p 10
###begin p 11
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Wynn1">[4]</xref>
###xml 303 304 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
It has been shown that fibrosis, which is a hallmark in PC, is strongly linked to the development of Th2 responses through activation by Th2 cytokines of collagen synthesis by fibroblasts and concomitant reduced collagen degradation in the absence of Th1 cytokines [4]. Therefore, the presence of GATA-3+ lymphoid cells, which we observed [3] in the pancreatic tumor microenvironment, might further contribute to fibrosis and local treatments aimed at reducing the presence of Th2 cytokines might be beneficial.
###end p 11
###begin p 12
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 100 103 100 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Constant1">[5]</xref>
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 285 288 285 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Trinchieri1">[6]</xref>
###xml 397 400 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Smits1">[7]</xref>
###xml 402 405 402 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Annunziato1">[8]</xref>
###xml 547 550 543 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-LopezRoa1">[9]</xref>
###xml 608 612 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Pflanz1">[10]</xref>
###xml 717 718 709 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 727 731 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Pflanz1">[10]</xref>
###xml 733 737 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Trinchieri2">[11]</xref>
###xml 772 776 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Yoshimoto1">[12]</xref>
###xml 833 834 825 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 888 896 880 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 363 368 <span type="species:ncbi:9606">human</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 823 829 <span type="species:ncbi:10090">murine</span>
Among the various factors that promote CD4+ T cells polarization, cytokines have a determinant role [5]. IL-12, a product of phagocytes and dendritic cells in response to microbial stimulation, has a major role in promoting Th1 polarization and in enhancing CD4+ T cells proliferation [6]. Moreover, IL-12 has been shown to induce reversal of Th2 polarization in human allergen-specific Th2 cells [7], [8] and, in synergy with IL-18, to stimulate IFN-gamma production of peripheral blood mononuclear cells (PBMC) from lepromatous leprosy patients [9]. IL-27, a recently identified member of the IL-12 family [10], also stimulates proliferation and synergizes with IL-12 in triggering IFN-gamma production of naive CD4+ T cells [10], [11]. More recently, it has been shown [12] that IL-27 inhibits Th2 polarization of naive murine CD4+ T cells and suppresses Th2 cytokines production from in vitro polarized Th2 cells.
###end p 12
###begin p 13
###xml 87 104 87 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide in vivo</italic>
###xml 128 129 128 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
In the present study we investigated the possibility to revert the Th2 polarization of bona fide in vivo primed CEA-specific CD4+ T cells from PC patients by using IL-12 and IL-27 as immunomodulating agents. We found that the presence of IL-27 alone was sufficient to inhibit IL-5 and IL-13 secretion, while IL-12 strongly stimulated IFN-gamma production with minor effects on Th2 cytokines secretion; the combination of the two cytokines induced a functional modulation of the Th2 polarization.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
Subjects and cell lines
###end title 15
###begin p 16
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 166 169 166 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 171 179 <span type="species:ncbi:9606">Patients</span>
###xml 578 583 <span type="species:ncbi:9606">human</span>
PBMC were obtained from two PC patients (pt#15 and pt#43) and one healthy donor (ND#11) of a cohort of subjects in which we previously detected anti-CEA CD4+ T cells [3]. Patients were drawn before surgery and staging of the disease was T3N1M0 in both cases. The Institutional Ethics Committee (Comitato Etico Fondazione Centro San Raffaele del Monte Tabor, Istituto Scientifico Ospedale San Raffaele) had approved the study protocol and written informed consent was obtained from all donors before blood sampling. EBV-transformed lymphoblastoid cell lines (LCL) used and their human leukocyte antigen (HLA)-DR type were: SKP-LCL (beta1*0405, *1401; beta3*02), established in our laboratory from a healthy donor; BM21 (beta1*1101; beta3*0202) and Pitout (beta1*0701; beta4*0101), kindly provided by K. Fleischhauer (San Raffaele Scientific Institute, Milan). LCL were cultured in RPMI 1640 (BioWhittaker) containing 2 mM L-glutamine, 100 units/ml penicillin, 50 mg/ml streptomycin (BioWhittaker), and 10% FCS (BioWhittaker).
###end p 16
###begin title 17
Synthesis of CEA peptides
###end title 17
###begin p 18
###xml 3 9 3 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99&#8211;111</sub>
###xml 14 21 14 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">117&#8211;129</sub>
###xml 26 41 26 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 46 53 46 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">425&#8211;437</sub>
###xml 58 65 58 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">568&#8211;582</sub>
###xml 74 81 74 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">666&#8211;678</sub>
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Curnis1">[13]</xref>
CEA99-111, CEA117-129, CEA177-189/355-367, CEA425-437, CEA568-582, and CEA666-678 sequences were synthesized by the stepwise solid-phase method as previously described [13]; the peptides were lyophilized, reconstituted in DMSO (Sigma-Aldrich) at 10 mg/ml and diluted in RPMI 1640 as needed.
###end p 18
###begin title 19
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vitro propagation of CD4+ T cell clones
###end title 19
###begin p 20
###xml 14 29 14 29 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Crosti1">[14]</xref>
###xml 357 362 <span type="species:ncbi:9606">human</span>
Polyclonal CEA177-189/355-367 specific CD4+ T cells from pt#15, obtained after 13 days of short-term culture with the specific peptide and autologous CD4+-depleted PBMC as antigen presenting cells (APC), were cloned by limiting dilution as described in [14]. The clones were cultured in X-VIVO 15 (BioWhittaker) supplemented with 5% heat-inactivated pooled human serum (BioWhittaker), penicillin (100 U/ml; BioWhittaker), streptomycin (50 mg/ml; BioWhittaker), and IL-2 (250 IU/ml; Proleukine, Novartis). Clones were re-stimulated every 15-21 days with phytohemagglutinin (PHA) (0,5 microg/ml; Sigma-Aldrich) and irradiated allogenic PBMC.
###end p 20
###begin title 21
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+ T cell clones stimulation assay
###end title 21
###begin p 22
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 181 182 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 215 230 212 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 322 327 <span type="species:ncbi:9606">human</span>
###xml 777 782 <span type="species:ncbi:9606">human</span>
###xml 1591 1596 <span type="species:ncbi:9606">Human</span>
CD4+ T cells (104/well) were cultured in triplicate in 96-U bottom plates in the presence of irradiated LCL (5x104/well), or irradiated autologous or HLA-DRbeta3*02 matched PBMC (105/well) as APC pulsed with the CEA177-189/355-367 peptide (10 microg/ml), or the purified CEA protein (30 microg/ml, BiosPacific), or normal human IgG (30 microg/ml, Venimmun N, Aventis Behring), as negative control. In inhibition experiments the following monoclonal antibodies (mAbs) (Beckton Dickinson) were used: anti-HLA-DR (100 ng/ml), anti-HLA-DP (3 microg/ml) and anti-HLA-DQ (125 ng/ml). In peptide titration experiments, the following concentrations of peptide were added: 20-10-5-1-0,5-0,1-0,05-0,01 and 0,005 microg/ml. In the experiments with immunomodulatory cytokines, recombinant human IL-12 and/or IL-27 (R&D Systems Inc.) were added at the following concentrations: IL-12, as single agent (5-20 ng/ml); IL-27, as single agent (0,01-1-10-100 ng/ml); combined IL-12 and IL-27 treatment (5 ng/ml+100 ng/ml, respectively). After 48 h, supernatant from each well was removed and pooled for cytokines' detection by ELISA, according to the manufacturers' instructions: GM-CSF (sensitivity threshold: 31,25 pg/ml) and transforming growth factor (TGF)-beta1 (sensitivity threshold: 62,5 pg/ml) (Biosource International Inc.); IFN-gamma, IL-5 and IL-13 (sensitivity threshold: 15,6 pg/ml) (Mabtech) and IL-17 (eBioscience) (sensitivity threshold: 7,8 pg/ml). IFN-gamma, tumor necrosis factor (TNF)-alpha, IL-10, IL-4, IL-5 and IL-2 release was also determined by using the Cytometric Beads Array (CBA) Human Th1-Th2 Cytokines Kit (sensitivity threshold: 20 pg/ml), (Becton Dickinson), following the manufacturer's instructions.
###end p 22
###begin title 23
Short-term culture and cytokine release assay
###end title 23
###begin p 24
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 112 115 112 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 606 607 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 722 727 <span type="species:ncbi:9606">human</span>
Purified CD4+ T cells were stimulated once in vitro in the presence of the CEA peptides as previously described [3]. Briefly, CD4+ T cells (3x104/well), purified from total PBMC by magnetic beads (Miltenyi Biotec), were plated in 96-well plates in five replicates for each condition and cultured in X-VIVO 15 supplemented with penicillin (100 U/ml), streptomycin (50 mg/ml) and 3% heat-inactivated pooled human serum (tissue culture medium, TCM), in the presence of irradiated CD4+-depleted PBMC as APC, at a CD4+: APC ratio of 1:3. Stimuli were: PHA (10 microg/ml; Sigma-Aldrich), as positive control; CD4+ T cells in the presence of the APC only, as baseline (blank); and each single peptide (10 microg/ml). Recombinant human IL-12 (5 ng/ml) and IL-27 (100 ng/ml) were added where indicated. At day 7, half medium from each well was removed and replenished with fresh TCM containing IL-2 (25 IU/ml), and IL-12 and IL-27 where indicated, without any further antigen stimulation. At day 14, supernatant was collected for IFN-gamma, IL-5, IL-13 and GM-CSF release by ELISA, as described above.
###end p 24
###begin title 25
Flow cytometry
###end title 25
###begin p 26
Cytofluorimetric analyses were performed on a FACSCalibur and analyzed using the FlowJo software (Tree Star, Inc.). The following antibodies were used: anti-CD3-APC, anti-CD4-PercP, anti-CCR4-PE, anti-CCR5-FITC (Pharmingen) and anti-CRTH2-PE (Miltenyi Biotec). TCRVbeta expression was determined with the IO Test Beta Mark kit (Immunotech), following the manufacturer's instruction.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 23 38 23 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Characterization of CEA177-189/355-367 specific Th2-cytokines producing CD4+ T cell clones
###end title 28
###begin p 29
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 152 155 152 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 252 267 252 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 332 340 332 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 485 493 485 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Seresini1">[15]</xref>
###xml 597 600 593 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 629 636 625 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 647 648 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 762 766 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 780 787 770 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1E</xref>
###xml 866 875 856 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
We previously reported that PC patients have a Th2 skew in anti-CEA CD4+ T cell immunity while maintaining an intact repertoire of anti-viral Th1 cells [3]. To better characterize the feature of this anti-CEA response we cloned by limiting dilution CEA177-189/355-367 specific polyclonal CD4+ T cells from pt #15, obtained after an in vitro short-term re-stimulation of CD4+ T cells with autologous APC pulsed with the relevant peptide; an assay that we previously showed not to favor in vitro priming [15]. Polyclonal cells produced high levels of IL-5 and very little of GM-CSF but no IFN-gamma [3], suggesting the presence of in vivo primed CD4+ T cells with Th2 features. Two clones were obtained, which expressed the same T cell receptor (TCR) Vbeta chain, i.e. the Vbeta17 (Fig. 1E), and therefore we used them indifferently in the following experiments being bona fide the same clone.
###end p 29
###begin title 30
###xml 23 38 23 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Characterization of CEA177-189/355-367 specific CD4+ T cell clones from pt#15.
###end title 30
###begin p 31
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Profile of cytokine secreted (A)</italic>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 428 447 426 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA restriction (B)</italic>
###xml 452 453 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 801 802 795 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1074 1078 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 1128 1129 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1253 1277 1245 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dose-response curves (C)</italic>
###xml 1282 1283 1274 1275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1504 1541 1494 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Recognition of the native protein (D)</italic>
###xml 1546 1547 1536 1537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1940 1944 1916 1920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 1994 1995 1970 1971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2138 2161 2114 2134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCRV&#946; expression (E)</italic>
###xml 2272 2341 2245 2314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Surface expression of Th2 (CRTH2 and CCR4) and Th1 (CCR5) markers (F)</italic>
###xml 1736 1741 <span type="species:ncbi:9606">human</span>
Profile of cytokine secreted (A). CD4+ T cells were cultured with irradiated APC in the presence or the absence of the relevant peptide in a 2-day stimulation assay and the concentration of the indicated cytokines in the supernatants was determined either by CBA (upper panel) or ELISA (lower panel). The data are representative of at least six experiments; for ELISA assays, the data are means of duplicate determination+/-SD. HLA restriction (B). CD4+ T cells were cultured with irradiated autologous PBMC or HLA-DR matched LCL, as indicated, in the presence or the absence of the relevant peptide (10 microg/ml) and in the absence or the presence of anti-HLA-DR, anti-HLA-DP and anti-HLA-DQ mAbs: after 2 days IL-5 was tested. Upper panel: % inhibition was calculated based on IL-5 secretion by CD4+ T cells in the presence of the relevant peptide (2 ng/ml over 0 ng/ml of background level). The data are representative of two (upper panel) and four (lower panel) experiments and are means of duplicate determination+/-SD. Responses significantly higher than the blanks (i.e., the basal levels of cytokines secretion from CD4+ T cells in the presence of LCL only) are indicated as: ***, p<0.001 (determined by unpaired, one-tailed Student's t test). Dose-response curves (C). CD4+ T cells were cultured with titrated doses of the relevant peptide in the presence of irradiated APC in a 2-day stimulation assay and tested for IL-5 and IL-13 release. The data are means of duplicate determination+/-SD. Recognition of the native protein (D). CD4+ T cells were cultured in the presence of irradiated PBMC, as APC, pulsed with either the relevant peptide (10 microg/ml) as positive control, or the purified CEA protein (30 microg/ml) or human IgG (30 microg/ml) as negative control in a 2-day stimulation assay and tested for IL-13 release. The data are means of duplicate determination+/-SD. Responses significantly higher than the blanks (i.e., the basal levels of cytokines secretion from CD4+ T cells in the presence of PBMC only) are indicated as: **, 0.001<p<0.05; ***, p<0.001 (determined by unpaired, one-tailed Student's t test). TCRVbeta expression (E). The test was performed with the IO Test Beta Mark kit. Quadrants were set based on isotype control staining. Surface expression of Th2 (CRTH2 and CCR4) and Th1 (CCR5) markers (F). Filled histograms represent isotype controls; open histograms samples stained with the indicated markers.
###end p 31
###begin p 32
###xml 31 46 31 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 85 93 85 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Figure 1</xref>
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 259 266 248 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1A</xref>
The characterization of the CEA177-189/355-367 specific CD4+ T clones is depicted in Figure 1. CD4+ T cell clones produced mainly IL-5, IL-13 and GM-CSF, while they released low amount of IL-4, and IFN-gamma and no IL-2, TNF-alpha, TGF-beta1, IL-10 or IL-17 (Fig. 1A). Although the cells produce little amount of IL-4, this pattern of cytokine secretion is consistent with a Th2 polarization.
###end p 32
###begin p 33
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 213 220 213 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1B</xref>
###xml 304 305 304 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 615 622 606 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1B</xref>
###xml 665 672 656 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1B</xref>
###xml 691 692 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 593 600 <span type="species:ncbi:9606">patient</span>
###xml 799 806 <span type="species:ncbi:9606">patient</span>
To identify the restriction element we first tested the recognition by CD4+ T cells of peptide loaded autologous APC in the absence or in the presence of anti-HLA-DR, anti-HLA-DP and anti-HLA-DQ mAbs. As shown in Fig. 1B (upper panel), addition of the anti-DR mAb inhibited (65,5%) IL-5 production by CD4+ T cells, demonstrating that an HLA-DR molecule presented the peptide. To identify the HLA-DR presenting allele, the cells were then challenged with the relevant peptide in the presence of LCL expressing different combinations of the HLA-DRbeta1, beta3 and beta4 alleles expressed by the patient (indicated in Fig. 1B) and tested for IL-5 release. As shown in Fig. 1B (lower panel), CD4+ T cells recognized the peptide in association with HLA-DRbeta3*02, which is the allele shared between the patient and the two presenting LCL (BM21 and SKP).
###end p 33
###begin p 34
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 135 142 135 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1C</xref>
We also performed peptide titration curve in which CD4+ T cells were challenged with increasing concentration of the relevant peptide (Fig. 1C). The experiments indicated the expression by the clone of a very low affinity TCR.
###end p 34
###begin p 35
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Campi1">[16]</xref>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 355 362 355 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1D</xref>
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 567 582 567 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 595 596 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 524 529 <span type="species:ncbi:9606">human</span>
We previously showed that CEA sequence repeated at positions 177-189 and 355-367 contains an in vitro naturally processed epitope presented in association with several HLA-DR alleles [16]. To confirm these data, CD4+ T cell clones were challenged with the CEA protein or normal human IgG, as a negative control, and assayed for IL-13 release. As shown in Fig. 1D, CD4+ T cells specifically produced IL-13 in the presence of the peptide and, most importantly, in the presence of the CEA but not of the control protein (i.e., human IgG), demonstrating that although CEA177-189/355-367 specific CD4+ T cell clones carry a low affinity TCR they recognize the native epitope.
###end p 35
###begin p 36
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Bonecchi1">[17]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Bonecchi1">[17]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Cosmi1">[18]</xref>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1F</xref>
Finally, to verify whether the Th2 cytokine profile correlated with the phenotypic markers of Th1 and Th2 cells, the clones were tested for the expression of CCR5, which is preferentially expressed by Th1 cells [17] and of CRTH2 and CCR4, whose expression characterizes Th2 cells [17], [18]. As expected from the cytokine profile, CD4+ T cells expressed on their surface both CRTH2 and CCR4 while CCR5 expression was absent (Fig. 1F).
###end p 36
###begin title 37
###xml 126 127 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Combined IL-27 and IL-12 treatment inhibits secretion of Th2 cytokines and stimulates IFN-gamma production by CEA specific CD4+ T cells
###end title 37
###begin p 38
###xml 70 85 70 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
We next tested the possibility to modulate the polarization of the CEA177-189/355-367-specific Th2 cells by the immunomodulatory cytokines IL-27 and IL-12.
###end p 38
###begin p 39
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 347 354 343 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g002">Fig. 2A</xref>
###xml 438 445 434 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g002">Fig. 2B</xref>
###xml 670 677 662 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g002">Fig. 2B</xref>
###xml 775 776 767 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To this aim we first evaluated the effect of increasing concentrations of IL-27 or IL-12, as single agents, on the production by CD4+ T cells of Th1 and Th2 cytokines in the presence of the relevant peptide. The addition of IL-27 decreased in a dose dependent-manner IL-5 and IL-13 production, while no effect was observed for IL-4 and IFN-gamma (Fig. 2A). The addition of IL-12 reached its plateau effect already at the dose of 5 ng/ml (Fig. 2B): IL-5 production decreased also in the presence of IL-12 while, at difference with IL-27, the effect on IL-13 was marginal as on IL-4. Importantly, and at difference with IL-27, IFN-gamma production was strongly increased (Fig. 2B). These data demonstrate that both cytokines affect the effector function of the CEA-specific CD4+ T cell clones but neither IL-27 nor IL-12, as single agents, were optimal in modulating their Th polarization.
###end p 39
###begin title 40
###xml 104 119 104 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Effect of titrated doses of IL-12 or IL-27 as single agent on the repertoire of cytokine secreted by CEA177-189/355-367 specific CD4+ T cells.
###end title 40
###begin p 41
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A).</italic>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 324 328 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(B).</italic>
###xml 332 333 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 503 504 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A). CD4+ T cells were cultured with the relevant peptide and irradiated LCL as APC in the presence of increasing concentrations of IL-27 (0-0,1-1-10-100 ng/ml); after 2 days the cytokine release was evaluated by CBA (IL-5 IL-4, and IFN-gamma) or ELISA (IL-13). The data for IL-13 are means of duplicate determination+/-SD. (B). CD4+ T cells were cultured and tested, as described above, in the presence of increasing concentrations of IL-12 (0-5-20 ng/ml). The basal level of cytokines secretion of CD4+ T cells in the presence of LCL only was subtracted from the sample values and was comprised between 0 and 0,018 ng/ml. The data are representative of at least three experiments.
###end p 41
###begin p 42
###xml 82 88 82 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g003">Fig. 3</xref>
Second, we evaluated the effect of the combined treatment with the two cytokines (Fig. 3). When used at 5 ng/ml, IL-12, as a single agent, induced 61% inhibition of IL-5 and had no effect on IL-13 and GM-CSF, while IFN-gamma production had almost a 10-fold increase. IL-27 treatment alone at the highest concentration showed 78%, 30% and 53% inhibition of IL-5, IL-13 and GM-CSF, respectively; while only 1,4-fold increase in IFN-gamma production. When used in combination at the best concentrations, a synergistic effect was observed in the inhibition of IL-5 (91%) and IL-13 (48%), while, as expected from the results of the single agents, GM-CSF secretion was not further inhibited and IFN-gamma production was not further increased.
###end p 42
###begin title 43
###xml 37 52 37 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Modulation of Th2 polarization of CEA177-189/355-367 specific CD4+ T cells by combined IL-12 and IL-27 treatment.
###end title 43
###begin p 44
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 440 441 434 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+ T cells were cultured with the relevant peptide in the absence (basal) or in the presence of IL-12 (5 ng/ml), as single agent; or IL-27 (100 ng/ml), as single agent; or combined IL-12 and IL-27 in a 2-day stimulation assay and then tested for cytokine release by CBA (IL-5 and IFN-gamma) or ELISA (IL-13 and GM-CSF). The data for IL-13 and GM-CSF are means of duplicate determination+/-SD. The basal level of cytokines secretion of CD4+ T cells in the presence of LCL only was subtracted from the sample values and was comprised between 0 and 0,006 ng/ml. The data are representative of five experiments.
###end p 44
###begin title 45
Modulation of Th2 polarization by IL-12 and IL-27 lasts after cytokines removal
###end title 45
###begin p 46
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 974 982 974 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g004">Figure 4</xref>
To verify whether the modulation of Th2 polarization obtained by the combined treatment with IL-12 and IL-27 was stable, we designed an experiment in which CEA-specific CD4+ T cells were first stimulated with the relevant peptide in the absence or in the presence of IL-12 and IL-27 (5 and 100 ng/ml, respectively). Second, cells stimulated in the absence of the cytokines were kept in culture for 14 days in TCM plus IL-2 and used as controls. Cells treated with the cytokines were divided in two aliquots and cultured under different conditions for the following 14 days: in one condition the cytokines were removed after 2 days and the cells cultured as the controls in TCM plus IL-2, in the other condition cytokines were kept in culture all the time and replaced every two to three days. At day 14, cells from each of the three conditions were tested in a 2-day stimulation assay with the relevant peptide and cytokine release tested. The results obtained are shown in Figure 4. Control cells confirmed production of IL-5, IL-13 and no IFN-gamma, while cells kept in culture continuously with the cytokines confirmed 98% and 74% inhibition of IL-5 and IL-13 production, respectively, and a 11-fold increase for IFN-gamma. Importantly, cells in which cytokines were removed after 2 days of culture still showed 70% and 47% inhibition in IL-5 and IL-13 production, respectively, and a 5-fold increase in IFN-gamma release.
###end p 46
###begin title 47
Effects of combined IL-12 and IL-27 given as a single shot or continuously in culture.
###end title 47
###begin p 48
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A)</italic>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 594 595 588 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 821 822 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 870 871 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(A). CD4+ T cells were cultured with the relevant peptide and either left untreated (peptide) or treated for 2 days with combined IL-12 (5 ng/ml) and IL-27 (100 ng/ml) and then washed and left untreated (IL-12+IL-27 (2-days)) or treated continuously with IL-12 and IL-27 at the same doses for 2 weeks (IL-12+IL-27 (14 days)). At day 14, cells were tested in the presence or the absence of the relevant peptide and the specific IL-5, IL-13 and IFN-gamma release in the supernatant tested by ELISA. The data are means of duplicate determination+/-SD. The basal level of cytokines secretion of CD4+ T cells in the presence of LCL only was subtracted from the sample values and was as follows: IL-5 (0,093+/-0,006 ng/ml), IL-13 (0,468+/-0,028 ng/ml) and IFN-gamma (0 ng/ml). The data are representative of four experiments. (B). Surface expression of CRTH2, CCR4 CCR5 by CD4+ T cells after treatment with combined IL-12+IL-27. Analysis was performed on cells treated for 2 days and then left untreated for a further week. Filled histograms represent isotype controls; open histograms samples stained with the indicated markers.
###end p 48
###begin p 49
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 313 322 313 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g004">Figure 4B</xref>
###xml 400 407 400 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g001">Fig. 1F</xref>
To verify whether the combined treatment also influenced the Th2 surface phenotype, CD4+ T cells, which had been re-stimulated in the presence of the cytokines for 2 days and then cultured for further seven days in the absence of the cytokines, were tested for the expression of CRTH2, CCR4 and CCR5. As shown in Figure 4B, the cells, while maintaining CRTH2 and CCR4 as in the absence of treatment (Fig. 1F), acquired the expression of CCR5.
###end p 49
###begin p 50
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Collectively, these results show that modulation of Th2 polarization of CEA-specific CD4+ T cell clones obtained with the combined treatment is lasting, although with reduced efficiency, even after cytokines removal and is associated with functional and phenotypic features of Th0 or both Th1 and Th2 cells.
###end p 50
###begin title 51
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
IL-12 and IL-27 combination enhances Th1 and modulates Th2 polarization of spontaneous anti-CEA CD4+ T cell responses
###end title 51
###begin p 52
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 251 259 251 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 399 407 399 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Figure 5</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 493 494 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 550 557 550 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">425&#8211;437</sub>
###xml 587 594 587 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">568&#8211;582</sub>
###xml 625 632 625 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">568&#8211;582</sub>
###xml 669 676 665 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">568&#8211;582</sub>
###xml 736 751 732 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 761 771 757 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 753 771 749 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Fig. 5, <italic>left panel</italic></xref>
###xml 771 783 767 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s, grey bars</italic>
###xml 901 908 897 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 951 958 943 950 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">425&#8211;437</sub>
###xml 1030 1045 1018 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">177&#8211;189/355&#8211;367</sub>
###xml 1177 1184 1161 1168 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">568&#8211;582</sub>
###xml 1194 1204 1178 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 1186 1204 1170 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Fig. 5, <italic>left panel</italic></xref>
###xml 1204 1217 1188 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s, black bars</italic>
###xml 1243 1246 1227 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 1300 1301 1284 1285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1354 1357 1338 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tassi1">[3]</xref>
###xml 1426 1432 1406 1412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99&#8211;111</sub>
###xml 1538 1549 1518 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 1530 1549 1510 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Fig. 5, <italic>right panel</italic></xref>
###xml 1549 1561 1529 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s, grey bars</italic>
###xml 1680 1686 1656 1662 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99&#8211;111</sub>
###xml 1770 1781 1746 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 1762 1781 1738 1757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Fig. 5, <italic>right panel</italic></xref>
###xml 1781 1794 1757 1770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s, black bars</italic>
###xml 2021 2028 1997 2004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de-novo</italic>
###xml 185 192 <span type="species:ncbi:9606">patient</span>
To verify the effect of combined IL-12 and IL-27 treatment on the polarization of CEA-specific CD4+ T cells in a more physiologic environment and at polyclonal level, CD4+ T cells from patient (pt#43) and normal donor (ND#11) were tested in a 14-days in vitro re-stimulation assay for the recognition of the relevant peptides in the absence or in the presence of the two immunomodulatory cytokines (Figure 5). As previously reported in [3], in the absence of the immunomodulatory cytokines CD4+ T cells from pt#43 produced IL-5 in the presence of CEA425-437; IL-13 in the presence of CEA568-582; GM-CSF in the presence of CEA568-582 and IFN-gamma in the presence of CEA568-582 and, although at a much lower but significant level, of CEA177-189/355-367 (Fig. 5, left panels, grey bars). The combination of IL-12 and IL-27 almost abolished IL-5 (99% inhibition) and IL-13 (76% inhibition) while induced de novo IFN-gamma secretion in the presence of CEA425-437, enhanced (9-fold increase) IFN-gamma production in the presence of CEA177-189/355-367 and confirmed IFN-gamma while strongly reduced IL-13 (98% inhibition) and GM-CSF (80% inhibition) production in the presence of CEA568-582 (Fig. 5, left panels, black bars). As previously reported [3], in the absence of the immunomodulatory cytokines CD4+ T cells from ND#11 showed significant proliferation [3] and very little amount of IFN-gamma secretion in the presence of CEA99-111, while no significant production of IL-5 and GM-CSF was observed in the presence of any peptide (Fig. 5, right panels, grey bars). IL-13 release was not tested. Cytokine treatment strongly augmented (23-fold increase) IFN-gamma release against CEA99-111, while, as expected, no effect on IL-5 and GM-CSF production was observed (Fig. 5, right panels, black bars). In both cases, the two cytokines induced modulation of Th2 or amplification of Th1 responses that were already present, although at very low level, in the absence of the cytokines combination, while there was no evidence of de-novo specific recognition of CEA peptides.
###end p 52
###begin title 53
###xml 136 137 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Combined treatment with IL-12 and IL-27 modulates polarization of Th2 and enhances IFN-gamma production by pre-existing Th1 anti-CEA CD4+ T cells.
###end title 53
###begin p 54
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 105 84 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
CD4+ T cells from pt#43 and ND#11 were cultured in five replicates, as described in Materials and Methods, with the responsive CEA peptides, in the absence (grey bars) or in the presence (black bars) of the combined treatment with IL-12 (5 ng/ml) plus IL-27 (100 ng/ml). After 14 days, IL-5, IL-13, GM-CSF and IFN-gamma release was tested by ELISA. Data reported are means of duplicate determination+/-SD. Dashed lines identify the basal level of cytokine secretion in the presence of APC only. n.d. = not determined.
###end p 54
###begin p 55
Collectively, these results suggest that IL-12 and IL-27 promote functional modulation of Th2-type and amplification of pre-existing Th1-type anti-CEA responses.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
In the present study, we report that the association of the immunomodulating cytokines IL-12 and IL-27 is able to modulate the functional polarization of anti-CEA Th2 CD4+ T cells from PC patients and to enhance pre-existing Th1 type anti-CEA CD4+ T cells.
###end p 57
###begin p 58
###xml 240 248 240 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Yoshimoto1">[12]</xref>
###xml 354 371 354 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide in vivo</italic>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 800 803 792 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Smits1">[7]</xref>
###xml 805 808 797 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Annunziato1">[8]</xref>
###xml 1260 1264 1248 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Varga1">[19]</xref>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 259 264 <span type="species:ncbi:10090">mouse</span>
###xml 861 866 <span type="species:ncbi:9606">human</span>
###xml 1251 1259 <span type="species:ncbi:9606">patients</span>
We show that treatment with IL-27 as a single agent inhibited both IL-5 and IL-13 release by CEA-specific Th2 cells. This confirms in the human system a previous report that described IL-27 as able to suppress Th2 cytokines production from in vitro polarized mouse Th2 cells [12]; but, at difference with this report, in our system in which we deal with bona fide in vivo polarized CD4+ T cells IL-27 had no effect on IFN-gamma secretion. Importantly, we also revealed a new function for IL-27 that is the inhibition of GM-CSF production. When IL-12 was used as a single agent, it strongly enhanced IFN-gamma production, while had only a marginal effect in suppressing the release of Th2 cytokines, and of IL-13 in particular and no effect on GM-CSF. This is also at difference with previous reports [7], [8], in which IL-12 was shown to revert polarization of human allergen specific Th2 cells by inducing IFN-gamma and inhibition of IL-4 production. Indeed, in the case of our clones IL-4, which however was not produced in high amounts, was not inhibited neither by IL-27 nor IL-12. The only Th2 cytokine affected by IL-12 was IL-5; this function was also previously reported for T cell clones obtained from the bronchoalveolar lavage of asthmatic patients [19].
###end p 58
###begin p 59
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 905 907 901 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</italic>
###xml 988 989 984 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1079 1080 1071 1072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1487 1488 1475 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Collectively, we show that in our system IL-12 and IL-27 have non redundant roles in modulating the polarization of established CEA-specific Th2 CD4+ T cells and that modulation of the functional and phenotypic Th2 polarization of anti-tumor CD4+ effectors into a Th0 type was obtained only in the presence of the combined synergistic treatment with the two cytokines. Modulation of the cytokines' production was, at least in the case of the clones, mostly functional with the induction of a rather peculiar phenotype where CCR4, CRTH2 and CCR5 expression coexisted (i.e., not typical of either Th1 or Th0 cells). Preliminary experiments (data not shown), in which we evaluated cytokines' production at single cell level by intracellular staining, indicated that: i) IL-27 alone did not affect the percentage of IL-5 and IL-13 or IFN-gamma producing cells both as single positive and double positive; and ii) IL-12 alone or the combination of the two cytokines induced a percentage of CD4+ T cells producing both Th2 cytokines and IFN-gamma without reduction in the number of CD4+ T cells producing Th2 cytokines. These results along with the previous ones on cytokine secretion in the supernatants exclude that the effect of IL-12 on IFN-gamma up-regulation is due to a subpopulation of Th1 cells that becomes preferentially expanded and suggest that the combination of IL-27 and IL-12 induces a reduction of Th2 cytokines secretion per single cell and reverts a small population of CD4+ Th2 cells, which then produce also high levels of IFN-gamma, to a Th0 type. Further experiments are needed to better define the mechanism of action of the two cytokines both as single agent and in combination.
###end p 59
###begin p 60
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 201 207 201 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007234-g005">Fig. 5</xref>
The effects of modulation of Th2 polarization seemed more effective for CEA-specific polyclonal CD4+ T cells where combined treatment was able to almost completely abolish IL-13 and GM-CSF production (Fig. 5). Although, we cannot exclude that in the latter case treatment with the cytokines might have affected not only the effectors but also the APC, which in turn might have further changed the cytokine milieu. To address this issue future studies should compare gene expression of different APC at basal level and after modulation with different cytokines' combination.
###end p 60
###begin p 61
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tatsumi1">[20]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Marturano1">[21]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Tatsumi2">[22]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Galon1">[23]</xref>
###xml 803 806 799 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Wynn1">[4]</xref>
###xml 972 976 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Filipazzi1">[24]</xref>
###xml 978 982 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Serafini1">[25]</xref>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
There are two main positive effects correlated to the modulation of the Th2 and enhancement of Th1 polarization of CEA-specific CD4+ T cells in PC. First, on the anti-tumor immunity: indeed, in human tumors a skew towards Th2 type of tumor-specific CD4+ T cells has been described in patients with advanced malignancies [20], [21], [22], while high levels of infiltrating Th1 cells in the tumors correlate with a better prognosis [23]. Second, on the tumor microenvironment, as fibrinogenesis and recruitment of myeloid suppressor cells are potentially inhibited. Indeed, Th2 cytokines and IL-13 in particular are strongly associated with stroma deposition, which is a peculiar feature of PC and is potentially involved in tumor progression, while IFN-gamma suppresses collagen synthesis by fibroblasts [4]. Furthermore, high levels of GM-CSF in anti-tumor vaccines enhance the recruitment of myeloid suppressor cells, thus potentially favoring immune-escape of the tumor [24], [25].
###end p 61
###begin p 62
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Overall, our results demonstrate that in vivo polarized Th2 CD4+ T cells specific for a tumor-associated antigen from PC patients are endowed with plasticity, and support further studies aimed at investigating the possible clinical application of the combination of IL-12 and IL-27 as a treatment for pancreatic cancer both as cytokines delivery and possibly for reprogramming tumor antigen specific T cells prior to adoptive immunotherapy.
###end p 62
###begin p 63
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Brunda1">[26]</xref>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Vagliani1">[27]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Colombo1">[28]</xref>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-DelVecchio1">[29]</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Heinzerling1">[30]</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Triozzi1">[31]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Mazzolini1">[32]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Hisada1">[33]</xref>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Shimizu1">[34]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Chiyo1">[35]</xref>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Oniki1">[36]</xref>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
###xml 550 555 <span type="species:ncbi:10090">mouse</span>
Treatment with systemic IL-12 of mouse cancer models has been shown to have a strong anti-tumor effect [26], [27]. However, systemic administration of IL-12, although stimulated anti-tumor immunity, had only minimal clinical efficacy in the presence of relevant side effects [28], [29]. Attempts to achieve IL-12 production only at the tumor site in melanoma and gastrointestinal carcinomas resulted instead in the absence of significant toxicity and in increased clinical responses, which correlated with increased inflammation [30], [31], [32]. In mouse models also IL-27 had a strong anti-tumor effect, which was enhanced by the presence of IL-12 [33], [34], [35], [36].
###end p 63
###begin p 64
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Neri1">[37]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Bellone1">[38]</xref>
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007234-Esposito1">[39]</xref>
To avoid systemic toxicity, strategies to selectively deliver various therapeutic compounds, including IL-12, to the tumor by tumor-specific antibodies or to the tumor vasculature have been recently developed [37], [38]. Of note, some of these strategies are directed towards tenascin, which is a component of the extracellular matrix and it is produced by pancreatic stellate cells, possibly under the influence of soluble factors released by tumor cells [39]. Therefore, tenascin could represent an interesting target for tumor-delivery of IL-12 and IL-27 in PC.
###end p 64
###begin p 65
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de-novo</italic>
The advantages of tumor targeted delivery of combined IL-12 and IL-27 in PC would be the modulation of the tumor microenvironment not only through their known effect on resident antigen presenting cells (and therefore on the de-novo priming of new Th1 effectors in the draining lymph nodes) but also directly on the modulation of the cytokines secreted by Th2 GATA-3+ infiltrating T cell effectors already present in the tumor by diminishing their negative effects on fibrinogenesis and recruitment of immunosuppressive myeloid dendritic cells, in the absence of systemic toxicity.
###end p 65
###begin p 66
We thank Paolo Dellabona and Matteo Bellone for critical reading of the manuscript.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
Pancreatic carcinoma.
###end article-title 68
###begin article-title 69
Pancreatic cancer microenvironment.
###end article-title 69
###begin article-title 70
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients.
###end article-title 70
###begin article-title 71
Fibrotic disease and the T(H)1/T(H)2 paradigm.
###end article-title 71
###begin article-title 72
Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.
###end article-title 72
###begin article-title 73
Interleukin-12 and the regulation of innate resistance and adaptive immunity.
###end article-title 73
###begin article-title 74
###xml 26 31 <span type="species:ncbi:9606">human</span>
IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression.
###end article-title 74
###begin article-title 75
###xml 12 17 <span type="species:ncbi:9606">human</span>
Reversal of human allergen-specific CRTH2+ T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide.
###end article-title 75
###begin article-title 76
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Recovery of IFN-gamma levels in PBMCs from lepromatous leprosy patients through the synergistic actions of the cytokines IL-12 and IL-18.
###end article-title 76
###begin article-title 77
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells.
###end article-title 77
###begin article-title 78
The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.
###end article-title 78
###begin article-title 79
IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation.
###end article-title 79
###begin article-title 80
Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.
###end article-title 80
###begin article-title 81
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients.
###end article-title 81
###begin article-title 82
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.
###end article-title 82
###begin article-title 83
###xml 54 62 <span type="species:ncbi:9606">patients</span>
CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope.
###end article-title 83
###begin article-title 84
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.
###end article-title 84
###begin article-title 85
###xml 67 72 <span type="species:ncbi:9606">human</span>
CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease.
###end article-title 85
###begin article-title 86
###xml 13 18 <span type="species:ncbi:9606">human</span>
T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro.
###end article-title 86
###begin article-title 87
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
###end article-title 87
###begin article-title 88
Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells.
###end article-title 88
###begin article-title 89
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
###end article-title 89
###begin article-title 90
###xml 51 56 <span type="species:ncbi:9606">human</span>
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
###end article-title 90
###begin article-title 91
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
###end article-title 91
###begin article-title 92
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
###end article-title 92
###begin article-title 93
###xml 64 70 <span type="species:ncbi:10090">murine</span>
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
###end article-title 93
###begin article-title 94
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.
###end article-title 94
###begin article-title 95
Interleukin-12 in anti-tumor immunity and immunotherapy.
###end article-title 95
###begin article-title 96
Interleukin-12: biological properties and clinical application.
###end article-title 96
###begin article-title 97
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy.
###end article-title 97
###begin article-title 98
###xml 45 60 <span type="species:ncbi:44088">canarypox virus</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
###end article-title 98
###begin article-title 99
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
###end article-title 99
###begin article-title 100
Potent antitumor activity of interleukin-27.
###end article-title 100
###begin article-title 101
Antiangiogenic and antitumor activities of IL-27.
###end article-title 101
###begin article-title 102
###xml 23 29 <span type="species:ncbi:10090">murine</span>
Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.
###end article-title 102
###begin article-title 103
Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
###end article-title 103
###begin article-title 104
Tumour vascular targeting.
###end article-title 104
###begin article-title 105
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer.
###end article-title 105
###begin article-title 106
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis.
###end article-title 106
###begin p 107
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 107
###begin p 108
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by the European Community (DC-THERA), the Italian Ministry of Health, the Italian Ministry of University and Scientific Research and the Rich Foundation (LDP Pancreas Cancer Research Project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 108

